Sickle Cell DiseaseThalassemiaHemolytic; Anemia, Hereditary, Due to Enzyme DisorderAnemia Due to Membrane DefectCDASideroblastic AnemiaConstitutional Aplastic AnemiaIron Metabolism DisordersHereditary Anemia
Investigational drug(s) / intervention(s)
Data collection from EHR.
Data collection from EHR.: Collection of clinical and laboratory data. Reviwe of the electronic health record
Study summary
Rare Anaemia Disorders (RADs) is a group of rare diseases characterized for presenting anaemia as the main clinical manifestation. Different medical entities classified as RADs by ORPHA classification are most of them chronic life threating disorders with many unmet needs for their proper clinical management creating an impact on European health systems. RADs present diagnostic challenges and their appropriate management requires from specialised multidisciplinary teams in Centers of expertise.
Although there are some examples of well-established national registries on RADs in EU, the lack of recommendations for Rare disease registries implementation and the lack of standards for interoperability has led to the fragmentation or unavailability of data on prevalence, survival, main clinical manifestations or treatments in most of the European countries.
Eligibility
Sex
ALL
Min age
0 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients must meet all of the following criteria to be included in the RADeep Registry
* Age from 0-100, both female and male
* Diagnosed as RADs (SCD, THAL, PKD, and other RADs THAL according to ORPHANET classification)
* Able and willing to provide written informed consent (patient or legal representative for minors)
Exclusion Criteria:
* Patient or legal representative for minors unwilling or unable to give consent
* Patients diagnosed with SCD or THAL (alpha-thalassaemia and beta-thalassaemia) traits or trait conditions for other recessive RADs
Primary outcome measure(s)
Estimation of Prevalence and Incidence of RADs — 15 years Demography and epidemiology
To collect and to describe demographics and epidemiological data of any type of RADs:
* Estimate the population frequency of each RAD disease group and disease survival
* Estimate the diagnosis delay
* Identify cohorts of patients for research/clinical trials
* Estimate disease severity
* Assess the use of specific treatments
Descriptive analyses will be undertaken at the end of the follow-up period using standard statistical methods to examine the subjects' demographics, disease characteristics and management. Data is updated yearly in an electronic CRF form while assuring homogenization in categorization and units.
Time-to-event analyses, namely Kaplan-Meier and Cox proportional hazard regression will be used to estimate overall survival.
Multivariate Cox proportional hazards regression models will be used to identify variables that are important to correlate survival.
Trial sites (1)
Facility
City
Region
Status
Vall d'hebron Research Institute - Vall d'Hebron Research Institute - University Hospital Vall d'Hebrón (VHIR/HUVH)
Barcelona
Catalonia
Recruiting
More Hospital Universitari Vall d'Hebron Research Institute trials in Spain
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.